ERBB2 and gastric cancer: Although a routinely used and studied biomarker, especially with the emergence of trastuzumab-resistant tumors, its prognostic value and distribution through different phenotypes remains unclear [4,5] A couple of studies reported Her2 as a prognostic factor only in stage I gastric cancer [6].